Post Doctoral Scientist, Synthetic Innovation Technologies at Eli Lilly and Company

San Diego, California, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Healthcare, BiotechnologyIndustries

Requirements

PhD in Organic Chemistry or related disciplines with all completed requirements by June 2026
A record of scientific contributions including peer-reviewed publications, presentations, and/or patents

Responsibilities

Keep safety as the top priority, striving to maintain a strong safety culture
Deliver high laboratory synthetic efficiency to accelerate the design-make-test-analyze cycle through the use of automated reaction screening approaches
Embrace a wide range of technologies, including: photoredox catalysis, flow chemistry, electrochemistry, organocatalysis, enzyme catalysis and laboratory automation
Effectively partner with instrument vendors to trouble-shoot equipment
Collaborate with colleagues specialized in medicinal chemistry, high-throughput automated synthesis, and process development

Skills

Synthetic Organic Chemistry

modern synthetic chemistry methodologies

hypothesis-based experimental design

problem-solving

scientific creativity

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free